AbbVie Inc. - 8-K Filing
AbbVie Inc. announced a definitive agreement to acquire Apogee Therapeutics on June 22, 2026 for $135.11 per share in cash, valuing the company at approximately $10.9 billion. The acquisition aims to expand AbbVie's immunology portfolio with clinical-stage assets including zumilokibart (APG777), a late-stage monoclonal antibody targeting IL-13 for atopic dermatitis and APG273, a long-acting combination therapy in development for asthma. (Items: 7.01 Regulation FD Disclosure On June 22, 2026, AbbVie Inc, 9.01 Financial Statements and Exhibits (d) Exhibits Exhibit No)
Tickers: $ABBV